The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of cancer drugs that target sugar-sensing molecules.
Immatics turned to existing investors and new partner Amgen to put together the round, which brings its total raised to date up toward €200 million.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe.
The idea is to manage the risks inherent in R&D by placing bets on eight to 10 early-stage assets and selling those that show promise in the clinic.
Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.
KSQ has interrogated 20,000 human genes across 600 cancer- and immune-based models, providing it with a wealth of data to power drug discovery.
The Paypal founder contributed to the series A Peptilogics put together to advance its lead treatment for multidrug-resistant bacterial infections.
After announcing this year’s Fierce 15 winners, we invited their executives to the Drug Development Forum in Boston to discuss some of the pivotal moments…